EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet

Yingying Shi, Jianbo Chen, Di Qu, Qiang Sun, Yang Yu, Hao Zhang, Zhengbo Liu, Jiyue Sha, Yinshi Sun iD

Nutrients · 15.03.2024 · 16 (6) · 842

DOI: 10.3390/nu16060842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, online erschienen am 15.03.2024. Verfasst von Yingying Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Ginsenosides, Gastrointestinal Microbiome. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, Jilin Provincial Department of Human Resources and Social Security, Jilin Province Science and Technology Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The primary objective of this investigation was to elucidate the manner in which ginsenoside Rg5 (Rg5) ameliorates nonalcoholic fatty liver disease (NAFLD) via the modulation of the gut microbiota milieu. We administered either a standard diet (ND) or a high-fat diet (HFD), coupled with 12-week treatment employing two distinct doses of Rg5 (50 and 100 mg/kg/d), to male C57BL/6J mice. In comparison to the HFD cohort, the Rg5-treated group demonstrated significant enhancements in biochemical parameters, exemplified by a substantial decrease in lipid concentrations, as well as the reduced expression of markers indicative of oxidative stress and liver injury. This signifies a mitigation of hepatic dysfunction induced by an HFD. Simultaneously, Rg5 demonstrates the capacity to activate the LKB1/AMPK/mTOR signaling pathway, instigating energy metabolism and consequently hindering the progression of NAFLD. Furthermore, we underscored the role of Rg5 in the treatment of NAFLD within the gut-microbiota-liver axis. Analysis via 16S rRNA sequencing unveiled that Rg5 intervention induced alterations in gut microbiota composition, fostering an increase in beneficial bacteria, such as Bacteroides and Akkermansia, while concurrently reducing the relative abundance of detrimental bacteria, exemplified by Olsenella. Furthermore, employing fecal microbiota transplantation (FMT) experiments, we observed analogous outcomes in mice subjected to fecal bacterial transplants, providing additional verification of the capacity of Rg5 to mitigate NAFLD in mice by actively participating in the restoration of gut microbiota via FMT. Drawing from these data, the regulation of the gut microbiota is recognized as an innovative strategy for treating or preventing NAFLD and metabolic syndrome. Consequently, these research findings suggest that Rg5 holds promise as a potential therapeutic agent for NAFLD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseGinsenosidesGastrointestinal MicrobiomeHumansMaleMiceAnimalsAMP-Activated Protein KinasesDiet, High-FatRNA, Ribosomal, 16SMice, Inbred C57BLLiverBacteriaTOR Serine-Threonine KinasesSignal Transduction

Stichwörter der Autor:innen

LKB1/AMPK/mTOR signaling pathwayfecal microbiota transplantationginsenoside Rg5nonalcoholic fatty liver disease

Substanzen

AMP-Activated Protein KinasesGinsenosidesRNA, Ribosomal, 16STOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
  • Institute of Special Wild Economic Animals and Plants, Chinese Academy of Agricultural Sciences, Changchun 130112, China.

ORCID-Profile: Yinshi Sun

Förderung

  • National Key Research and Development Program
  • Jilin Provincial Department of Human Resources and Social Security
  • Jilin Province Science and Technology Development Program

Zitieren

APA

Shi, Y., Chen, J., Qu, D., Sun, Q., Yu, Y., Zhang, H., Liu, Z., Sha, J., & Sun, Y. (2024). Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet. Nutrients, 16(6), 842. https://doi.org/10.3390/nu16060842

Vancouver

Shi Y, Chen J, Qu D, Sun Q, Yu Y, Zhang H, et al. Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet. Nutrients. 2024;16(6):842. doi:10.3390/nu16060842

BibTeX
@article{Shi2024,
  author = {Shi, Yingying and Chen, Jianbo and Qu, Di and Sun, Qiang and Yu, Yang and Zhang, Hao and Liu, Zhengbo and Sha, Jiyue and Sun, Yinshi},
  title = {Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {842},
  doi = {10.3390/nu16060842}
}
Kostenlos starten →